Spikimm is a biotech company co-created by Truffle Capital and Institut Pasteur with the objective of developing an effective treatment against SARS-CoV2 and its major variants.
SpikImm was founded in 2021 by Truffle Capital and the Institut Pasteur to develop human monoclonal antibodies (mAbs) to prevent COVID-19.
SPK001 and SPK002, SpikImm‘s lead candidates, originally developed in the laboratory of Humoral Immunology (Institut Pasteur & Inserm) headed by Dr Hugo MOUQUET, have demonstrated a potent and broad neutralization activity in vitro against SARS-CoV-2 and variants of concern, as well as a therapeutic efficacy in vivo in mouse and hamster models.
Results have been published in June 2022 in Journal of Experimental Medicine (JEM).
SPK001 and SPK002 are developed as a long-acting antibody with a convenient, intramuscular administration for the prevention of COVID-19 (pre-exposure prophylaxis) in immunocompromised patients unable to mount a protective antibody response after vaccination.
SpikImm has recently dosed the first subject in a phase 1 clinical trial of SPK001. SpikImm then expects to demonstrate the medical benefit in a phase 2 in immunocompromised patients. Depending on the results, SPK001 may seek Emergency Use Authorization (EUA) as from Q2 2023.